Autonomic Dysreflexia as a Potential Adverse Effect of Duloxetine and Amitriptyline Combination Therapy: A Case Report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30036681.
- Also identified by DOI 10.1016/j.pmrj.2018.07.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pharmacologic triggers of autonomic dysreflexia (AD) have rarely been described. This report describes the case of a 31-year-old woman with T3 American Spinal Injury Association Impairment Scale A spinal cord injury who developed recurrent AD while receiving duloxetine and amitriptyline combination therapy for neuropathic pain. After excluding other AD generators, duloxetine was discontinued and the AD episodes resolved. Although secondary hypertension is a known side effect of amitriptyline and duloxetine, neither drug has been previously associated with AD. One potential mechanism for inhibition of duloxetine metabolism is discussed. Unexplained AD in at-risk patients receiving duloxetine and amitriptyline should prompt consideration of an adverse reaction to combination therapy. LEVEL OF EVIDENCE: V.
Medical subject headings
- Amitriptyline
- Autonomic Dysreflexia
- Duloxetine Hydrochloride